TruAlt Bioenergy Subsidiary Secures ₹130 Million Investment from GAIL for CBG Projects
TruAlt Bioenergy's subsidiary, Leafiniti Bioenergy, will receive ₹130 million from GAIL (India) Limited for new Compressed Biogas (CBG) projects. GAIL will acquire a 49% equity stake, with TruAlt retaining 51%. The investment will fund greenfield CBG plants, aiming to bolster India's energy transition and reduce fossil fuel reliance.
The substantial investment from a major player like GAIL into TruAlt's subsidiary for expanding CBG projects is a significant development. It directly impacts the company's growth strategy, market presence in the clean energy sector, and its contribution to national energy goals, indicating a high level of impact.
The investment from GAIL into TruAlt Bioenergy's subsidiary is a positive development, strengthening the company's position in the growing Compressed Biogas sector and contributing to India's energy transition goals. It signifies a strategic partnership and expansion, which is inherently positive for the company's growth prospects.
TruAlt Bioenergy Limited announced that its subsidiary, Leafiniti Bioenergy Private Limited (LBPL), has received a strategic investment of ₹130 million from GAIL (India) Limited. This investment, made pursuant to a Share Subscription-cum-Shareholders’ Agreement executed on August 11, 2025, is aimed at advancing TruAlt's Compressed Biogas (CBG) portfolio and strengthening India's energy transition.
Under the terms of the agreement, GAIL will acquire a 49% equity stake in Leafiniti by investing an aggregate amount of ₹13,54,32,150 (₹130 million). This capital will be deployed towards new CBG projects. Following the transaction, TruAlt will retain a 51% stake, with GAIL holding 49%, establishing a balanced strategic partnership. The investment is structured to align with project approvals and governance mechanisms for disciplined capital allocation and phased expansion.
The collaboration will leverage TruAlt's bioenergy expertise with GAIL's gas infrastructure and market reach to establish greenfield CBG plants in Karnataka, Maharashtra, and Odisha. The first phase involves six plants, each with a capacity of 12 tonnes per day, primarily using sugar mill residues. This phase is expected to produce 23,976 tonnes of CBG annually, create 820 to 1,225 jobs, and generate 97,902 tonnes of Fermented Organic Manure (FOM) and 4,70,862 tonnes of Liquid Fermented Organic Manure (LFOM) annually. Environmentally, this phase is projected to displace 19,800 tonnes of fossil fuels and avoid 9,300 tonnes of methane emissions per annum.
Vijay Nirani, Founder & Managing Director of TruAlt Bioenergy, highlighted the strategic importance of CBG for India's energy security and self-reliance, emphasizing the conversion of agricultural resources into indigenous energy and the central role of farmers. Rajeev Kumar Singhal, Director Business Development at GAIL, noted the potential to reduce foreign exchange outflows and strengthen energy security by scaling up CBG production, complementing GAIL's marketing expertise with TruAlt's operational experience.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.